Clinical Trial Update: Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT [Phase 3]

View source ↗

Summary

Phase 3 long-term safety update for latanoprostene bunod ophthalmic solution 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024% (latanoprostene bunod ophthalmic solution 0.024%)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2018-06-06